# Institut de Recherche en Cancérologie de Montpellier

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/institut-de-recherche-en-cancerologie-de-montpellier/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 54.7 |
| Citations | 510,275 |
| City | Montpellier |
| Country | FR |
| Description | Institut de Recherche en Cancérologie de Montpellier is a research organisation in Montpellier, FR. OpenAlex records 5,224 works and 510,275 citations for it. 1,122 researchers list it as their most recent affiliation. |
| Homepage | https://ircm.fr/index.php?project=crcm_en |
| OpenAlex ID | https://openalex.org/I4210140335 |
| Region | Occitanie |
| Researchers | 1,122 |
| ROR ID | https://ror.org/03capj968 |
| Type | facility |
| Works | 5,224 |

## University papers

- [Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-emtansine-for-residual-invasive-her2-positive-breast-cancer/)
- [Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer/)
- [Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer](https://scholariq.org/papers/2019-international-clinical-practice-guidelines-for-the-treatment-and/)
- [Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study](https://scholariq.org/papers/durvalumab-with-or-without-bevacizumab-with-transarterial-chemoembolisation-in/)
- [KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma](https://scholariq.org/papers/kras-g12d-mutation-subtype-is-a-prognostic-factor-for-advanced-pancreatic/)
- [Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer](https://scholariq.org/papers/full-length-cytokeratin-19-is-released-by-human-tumor-cells-a-potential-role-in/)

## University top topics

Showing 8 of 25.

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.